Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study

Objective Patients with short bowel syndrome (SBS) and colon in continuity have better adaptation potential compared with patients with jejunostomy. Adaptation may involve enhanced postprandial secretion of the enteroendocrine hormones glucagon-like peptide (GLP)-1 and GLP-2 which are normally degra...

Full description

Bibliographic Details
Main Authors: Bolette Hartmann, Jens Juul Holst, Rahim Mohammad Naimi, Mark Krogh Hvistendahl, Lise Margrete Thomassen, Hanna Johnsen, Charlotte Bayer Christiansen, Palle Bekker Jeppesen
Format: Article
Language:English
Published: BMJ Publishing Group 2021-09-01
Series:BMJ Open Gastroenterology
Online Access:https://bmjopengastro.bmj.com/content/8/1/e000604.full

Internet

https://bmjopengastro.bmj.com/content/8/1/e000604.full

Similar Items